Virios Therapeutics Announces Publication Of International Patent For IMC-2 Covering Antiviral Treatment Of Long-COVID
Portfolio Pulse from Benzinga Newsdesk
Virios Therapeutics, Inc. (NASDAQ:VIRI) announced the publication of an international patent for IMC-2, aimed at treating Long-COVID (LC) symptoms. The patent, published by the World Intellectual Property Organization, covers the use of a combination of valacyclovir and celecoxib for treating LC, including fatigue and cognitive dysfunction. Preliminary studies show significant reductions in LC symptoms, with further results expected from an ongoing trial. The potential market includes over 45 million adults in the US, highlighting a significant need for effective LC treatments.
March 26, 2024 | 1:17 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Virios Therapeutics' announcement of an international patent for IMC-2 to treat Long-COVID could significantly enhance its market position and potential revenue streams. The patent and promising preliminary study results may attract investor interest, especially with the large potential market.
The publication of the international patent for IMC-2 by Virios Therapeutics represents a significant step in addressing the unmet medical need for Long-COVID treatments. Given the lack of FDA-approved treatments for Long-COVID symptoms and the large potential market, this development could positively impact VIRI's stock in the short term. The confidence in this analysis is based on the clear connection between the patent announcement, the potential market size, and the preliminary positive results from the ongoing study.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100